Home › Ovarian Cancer › North Carolina
Ovarian Cancer clinical trials in North Carolina
44 studies for Ovarian Cancer are looking for participants at sites in North Carolina.
Cities in North Carolina
The Vanguard Study: Testing a New Way to Screen for Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Durham VA Medical Center, Durham
RecruitingHealthy volunteers welcome
Ages 45 to 75 · All sexes · Updated Oct 5, 2026 · NCT06995898Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- University of North Carolina-Hillsborough Campus, Hillsborough
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07001748Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Cone Health MedCenter Asheboro, Asheboro
- Cone Health Cancer Center at Alamance Regional, Burlington
- Southeastern Medical Oncology Center-Clinton, Clinton
- and 9 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 5, 2026 · NCT05564377A Study of PHST001 in Advanced Solid Tumors
- Duke Cancer Institute, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06840886A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Carolina Cancer Research Center, Wilson
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Duke University, Durham
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Novant Health Cancer Institute - Kernersville, Kernersville
- Novant Health Cancer Institute - Mount Airy, Mount Airy
- Novant Health Forsyth Medical Center, Winston-Salem
Recruiting
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07059884Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07360314A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- University of North Carolina Medical Center /ID# 275307, Chapel Hill
- Atrium Health Levine Cancer Institute /ID# 274557, Charlotte
- East Carolina University - Brody School of Medicine /ID# 275770, Greenville
- and 1 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT06890338A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Site 0259 - Duke Cancer Center, Durham
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05128825DESTINY-PANTUMOUR04
- Research Site, Durham
- Research Site, Wilson
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Duke Cancer Institute, Durham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213804A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07213791A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- FirstHealth of the Carolinas- Speciality Center /ID# 278636, Pinehurst
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 22, 2026 · NCT07059845A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Duke Cancer Center ( Site 0012), Durham
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 17, 2026 · NCT07318558Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Levine Cancer Center, Charlotte
- Novant Presbyterian Hospital, Charlotte
- East Carolina University, Greenville
- and 2 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 15, 2026 · NCT07214779ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- UNC- Chapel Hill, Chapel Hill
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
- Duke, Durham
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 14, 2026 · NCT04575935A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Charlotte
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05123482A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- FirstHealth Cancer Center ( Site 0079), Pinehurst
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06824467Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Levine Cancer Institute, Charlotte
- East Carolina University, Greenville
- Atrium Health Wake Forest Baptist, Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 3
Ages 18 and older · Women · Updated Aug 26, 2026 · NCT05281471A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- Atrium Health - Wake Forest, Charlotte
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07470853A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Mission Hospital, Asheville
- Hope Women's Cancer Centers-Asheville, Asheville
- Duke Cancer Center Cary, Cary
- and 7 more
Recruiting
Ages 35 to 50 · Women · Updated Aug 7, 2026 · NCT04251052A Study of DM002 in Patients With Advanced Solid Tumors
- Carolina BioOncology Institute, LLC, Huntersville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06751329Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Duke University Medical Center, Durham
- Duke Women's Cancer Care Raleigh, Raleigh
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT06580314A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, Huntersville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT07749586A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797The Better, Harder, Faster, Stronger Study
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecruitingObservational study
Ages 55 and older · Women · Updated Jul 15, 2026 · NCT07220512CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
- Duke University, Durham
RecruitingPhase 1/2
Ages 18 to 75 · Women · Updated Jul 13, 2026 · NCT07322094Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- UNC Hospital, Chapel Hill
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 2, 2026 · NCT06819007Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- GSK Investigational Site, Charlotte
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT04641247Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Carolina BioOncology Institute, Huntersville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT06993844Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
- Lineberger Comprehensive Cancer Center, Chapel Hill
RecruitingPhase 1
Ages 18 and older · Women · Updated May 19, 2026 · NCT06305299Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- Duke Cancer Center, Durham
- Duke Women's Cancer Care Raleigh, Raleigh
RecruitingPhase 3
Ages 18 and older · Women · Updated Apr 16, 2026 · NCT05659381REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
- Duke Cancer Center, Durham
Recruiting
Ages 18 and older · Women · Updated Apr 13, 2026 · NCT06710548A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
- Site 0259, Durham
RecruitingPhase 1
Ages 18 and older · Women · Updated Apr 7, 2026 · NCT04516447TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
- Duke University Hospital, Durham
Recruiting
Ages 25 to 50 · Women · Updated Apr 6, 2026 · NCT04294927Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- Levine Cancer Institute (LCI)- Atrium Health, Charlotte
- Duke Cancer Center/ DUMC, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 1, 2026 · NCT05735080A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Duke Cancer Institute, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.